Frost & Sullivan Recognizes Potential for its ‘Groundbreaking’ Functionality
EINDHOVEN, The Netherlands (November 29, 2015) Medtech innovator Medimetrics has won the 2015 Frost & Sullivan Award for ‘Product Innovation in Personalized Drug Delivery’ for its IntelliCap micro-electronics, oral drug delivery system. The award is open to companies trading in North America.
IntelliCap enables the precise delivery of drugs in the gastro-intestinal tract and the measurement and reporting of conditions in the body.
The official Frost & Sullivan report recognizes the ability of the IntelliCap delivery platform to ‘improve the analytical accuracy of clinical trials’. This comes at a time when the cost of the entire development process for a prescription drug is currently estimated to be around $2.6 billion*. Frost & Sullivan notes that the IntelliCap technology offers drug developers the potential to create new smart pharmaceutical therapies – and bring them to the market faster.
Yves Decadt, the Medimetrics CEO, explained: “The spirit of the award was to recognize the potential of the IntelliCap technology, with its unique ability to adapt and personalize during drug delivery.
“Medimetrics is especially well placed to play a leading role in the emerging world of digital health, actively involved in the development of smart pharmaceuticals which improve outcomes for patients.”
In deciding the winner, Frost & Sullivan analysts carried out independent analysis which focused on two key factors – ‘New Product Attributes and Customer Impact’. Some of the key benefits of the IntelliCap technology highlighted in their report included:
• Delivery of faster results while maintaining reliability
• Diverse functionality in one capsule replacing need for multiple devices
• Greater efficiency from suite of functionalities
• Time-saving, streamlined testing process
• Quantification of individual GI transit data rather than average values
• Improved accuracy when determining drug absorption.
Michael Valenti, Frost & Sullivan, Senior Consultant - Technical Insights, said: “Increasingly complex clinical trials have contributed to the increasing cost of developing a prescription drug. By developing an ingestible drug delivery system with two-way communications to an external data monitoring unit, Medimetrics Personalized Drug Delivery promises to reduce the complexity, time and cost of those trials with its novel combination of functionality.
“The Medimetrics IntelliCap system enables researchers to deliver precise amounts of developmental medicine to optimal parts of the patient’s body, monitor physical parameters, and track the movement of the drug delivery system through the body.”
-more-
IntelliCap Oral Drug Delivery System Wins Product Innovation Award/page 2 of 2
The wireless controlled, interactive IntelliCap CR system has CE Marking for the aspiration of fluids as well as the drug delivery and real-time measurement of temperature and pH in the gut. An increasing number of pharma companies are using this powerful tool in the early-stage development and life cycle management of drugs. It enables personalization of medications and treatments, empowering scientists to establish quickly the effective medication dose and delivery requirements. This reduces the risk of failure in expensive, late stage clinical trials, due to lack of safety or efficacy.
IntelliCap in action
Recent developments have seen expansion into microbiome research and novel therapeutic solutions in women’s health. In conjunction with NIZO food research and Wageningen University, the IntelliCap technology is opening up research opportunities into the impact of the small intestine microbiota on health and disease. Early indications for a joint study, due to be published at the beginning of 2016, show that, for the first time, scientists have been able to obtain and analyse samples of the small intestine’s microbiome in a non-invasive way. In the field of women’s health, LiGalli, a pioneering Dutch company led by Dr. Willem de Laat, is working with Medimetrics to integrate the technology into a novel vaginal drug delivery system that would enable revolutionary new therapies.
Medimetrics Personalized Drug Delivery B.V.is the pioneer and global leader in electronic oral drug delivery and is committed to innovating healthcare. Medimetrics has created the IntelliCap® system for precise delivery of drugs in the gastro-intestinal tract and the measurement and reporting of conditions in the body. It is the world’s first and only smart oral electronic drug delivery system. Available as an R&D service the IntelliCap® system is a highly effective tool for targeted, modified release formulation development. Available by license and co-development, the IntelliCap® technology is applied to create revolutionary new smart pharmaceutical products. Medimetrics has locations in the Netherlands, USA, and Germany.
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.
*According to the Tufts Center for the Study of Drug Development report, the cost of the entire development process for a prescription drug that gains market approval amounted to $2.6 billion in 2014, increasing by 145% from 2003 after inflation.
IntelliCap is a registered trademark of Medimetrics Personalized Drug Delivery B.V. in the USA and Europe.
